|
1.American Cancer Society. Cancer Facts and Figures 2012. http://www.cancer.org/research/cancerfactsstatistics/index., (2012). 2.Health Promotion Administration, Ministry of Health and Welfare. http://www.hpa.gov.tw/BHPNet/Web/Index/Index.aspx, (2015). 3.N. Cancer Genome Atlas Research et al., Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013). 4.H. Heyn, M. Esteller, DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13, 679-692 (2012). 5.T. A. Rauch et al., DNA methylation biomarkers for lung cancer. Tumour Biol 33, 287-296 (2012). 6.A. K. Greenberg, M. S. Lee, Biomarkers for lung cancer: clinical uses. Current opinion in pulmonary medicine 13, 249-255 (2007). 7.L. Guzmán et al., Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol 7, 1596-1597 (2012). 8.T. Wittenberger et al., DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics 6, 311-327 (2014). 9.M. Fukunaga, K. Nomura, E. Ishikawa, S. Ushigome, Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30, 249-255 (1997). 10.F. Ballouk, J. S. Ross, B. C. Wolf, Ovarian endometriotic cysts. An analysis of cytologic atypia and DNA ploidy patterns. Am J Clin Pathol 102, 415-419 (1994). 11.R. Sainz de la Cuesta, M. Izquierdo, M. Canamero, J. J. Granizo, F. Manzarbeitia, Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 113, 87-93 (2004). 12.M. G. del Carmen et al., Endometriosis-associated ovarian carcinoma. Cancer 98, 1658-1663 (2003). 13.E. Chalas, J. ChumasS, R. Barbieri, W. J. Mann, Nucleolar organizer regions in endometriosis, atypical endometriosis, and clear cell and endometrioid carcinomas. Gynecologic oncology 40, 260-263 (1990). 14.B. MacMahon, Risk factors for endometrial cancer. Gynecologic oncology 2, 122-129 (1974). 15.Disaia PJ, C. WT, Clinical Gynecologic Oncology 5th Ed . Mosby Year Book St. Louis 2, 134-167 (1997 ). 16.K. J. Ryan, R. S. Berkowitz, R. L. Barbieri, A. Dunaif, Kistner's Gynecology and Women's Health. 7, 89-95 (1999). 17.A. Burleigh, A. Talhouk, C. B. Gilks, J. N. McAlpine, Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors. Gynecologic oncology 138, 141-146 (2015). 18.T. Bese, Y. Simsek, N. Bese, S. Ilvan, M. Arvas, Extensive pelvic endometriosis with malignant change in tamoxifen‐treated postmenopausal women. International Journal of Gynecological Cancer 13, 376-380 (2003). 19.S. S. Bassuk, J. E. Manson, Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Annals of epidemiology 25, 193-200 (2015). 20.J. Wijnen et al., Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature genetics 23, 142-144 (1999). 21.F. Turati et al., Family history of cancer and the risk of cancer: a network of case–control studies. Annals of oncology, mdt280 (2013). 22.Y. L. Woo, P. L. Cheah, S. I. Shahruddin, S. Z. Omar, M. Arends, The immunohistochemistry signature of mismatch repair (MMR) proteins in a multiethnic Asian cohort with endometrial carcinoma. International Journal of Gynecologic Pathology 33, 554-559 (2014). 23.A. K. Win, J. C. Reece, S. Ryan, Family History and Risk of Endometrial Cancer: A Systematic Review and Meta-analysis. Obstetrics & Gynecology 125, 89-98 (2015). 24.L. S. Cook et al., Endometrial cancer and a family history of cancer. Gynecologic oncology 130, 334-339 (2013). 25.A. K. Win et al., Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. Journal of the National Cancer Institute 105, 274-279 (2013). 26.N. Burbos et al., Estimating the risk of endometrial cancer in symptomatic postmenopausal women: a novel clinical prediction model based on patients' characteristics. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 21, 500-506 (2011). 27.T. Ikeda et al., Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncology reports 7, 567-637 (2000). 28.D. M. Dinulescu et al., Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature medicine 11, 63-70 (2005). 29.Y. Mizumoto et al., Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer science 98, 652-658 (2007). 30.Y. Liu et al., Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Journal of the National Cancer Institute 106, dju245 (2014). 31.A. S. Lukes et al., Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer. Cancer 73, 2380-2385 (1994). 32.R. A. Nout et al., Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation. Gynecologic oncology 126, 466-473 (2012). 33.A. Doll et al., Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108, 221-229 (2008). 34.N. Colombo et al., Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6, vi33-38 (2013). 35.J. M. Duk, J. G. Aalders, G. J. Fleuren, H. W. de Bruijn, CA 125: a useful marker in endometrial carcinoma. American journal of obstetrics and gynecology 155, 1097-1102 (1986). 36.T. Tanaka et al., Preoperative MRI and intraoperative frozen section diagnosis of myometrial invasion in patients with endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 25, 879-883 (2015). 37.E. Epstein, L. Blomqvist, Imaging in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 28, 721-739 (2014). 38.P. A. Jones, S. B. Baylin, The fundamental role of epigenetic events in cancer. Nature reviews genetics 3, 415-428 (2002). 39.R. Kanwal, S. Gupta, Epigenetic modifications in cancer. Clin Genet 81, 303-311 (2012). 40.M. A. Glozak, E. Seto, Histone deacetylases and cancer. Oncogene 26, 5420-5432 (2007). 41.M. Gardiner-Garden, M. Frommer, CpG islands in vertebrate genomes. J Mol Biol 196, 261-282 (1987). 42.K. Banno et al., Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 4, 147-162 (2012). 43.R. Kanwal, S. Gupta, Epigenetic modifications in cancer. Clinical genetics 81, 303-311 (2012). 44.P. Su et al., Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene 32, 15-26 (2013). 45.Y. Muraki et al., Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer (Review). Oncology reports 22, 967-972 (2009). 46.Y. Zhao et al., A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer research 74, 5103-5117 (2014). 47.L. M. De Strooper et al., CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. Journal of clinical pathology 67, 1067-1071 (2014). 48.N. Wentzensen et al., Discovery and validation of methylation markers for endometrial cancer. Int J Cancer 135, 1860-1868 (2014). 49.K. Doufekas et al., GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 23, 1050-1055 (2013). 50.J. N. Bakkum-Gamez et al., Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic oncology 137, 14-22 (2015). 51.A. Jones et al., Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med 10, e1001551 (2013). 52.P. Dehan et al., Expression of type 2 orexin receptor in human endometrium and its epigenetic silencing in endometrial cancer. J Clin Endocrinol Metab 98, 1549-1557 (2013). 53.T. Yang et al., Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma. PloS one 8, e67458 (2013). 54.N. A. Wentzensen et al., DNA methylation profiles of endometrial cancer and benign endometrium suggest differences by mismatch repair status and possible early detection markers. Cancer Research 72, 5012 (2012). 55.H.-C. Lai et al., DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. Gynecologic oncology 135, 552-559 (2014). 56.R. Dong et al., TESTIN was commonly hypermethylated and involved in the epithelial‐mesenchymal transition of endometrial cancer. Apmis 123, 394-400 (2015). 57.Y.-W. Huang et al., Hypermethylation of miR-203 in endometrial carcinomas. Gynecologic oncology 133, 340-345 (2014). 58.Y.-W. Huang et al., Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer research 69, 9038-9046 (2009). 59.T. Tsuruta et al., miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer research, caners. 0364-2011 (2011). 60.Y.-T. Hsu et al., Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clinical Cancer Research 19, 6272-6285 (2013). 61.I. Kinde et al., Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Science translational medicine 5, 167ra164-167ra164 (2013). 62.C.-J. W. P-L Tsou, MD Anderson Cancer Center The Cancer Genome Atlas. 24, 43-47 (2013). 63.R. S. Day et al., Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics 12, 213 (2011). 64.EBIOTECH, Gene express analysis topics. 2, 23-32 (2011). 65.J. S. Kim et al., Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118, 2454-2465 (2012). 66.M. Azrad, W. Demark-Wahnefried, The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Current nutrition reports 3, 9-15 (2014). 67.T. Evans et al., Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. British journal of cancer 104, 1505-1510 (2011). 68.N. van Hanegem et al., Diagnostic evaluation of the endometrium in postmenopausal bleeding: An evidence-based approach. Maturitas 68, 155-164 (2011). 69.M. L. Torres et al., Risk factors for developing endometrial cancer after benign endometrial sampling. Obstetrics and gynecology 120, 998 (2012). 70.M. E. Sherman et al., Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. International Journal of Gynecologic Pathology 27, 318-325 (2008). 71.C. L. Trimble et al., Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia. Cancer 106, 812-819 (2006). 72.C. L. Trimble et al., Management of endometrial precancers. Obstetrics and gynecology 120, 1160 (2012). 73.A. Widschwendter et al., Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clinical cancer research 10, 3396-3400 (2004). 74.Y. Liu et al., Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 106, (2014). 75.I. Kinde et al., Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5, 167ra164 (2013). 76.H. Fiegl et al., Methylated DNA collected by tampons—a new tool to detect endometrial cancer. Cancer Epidemiology Biomarkers & Prevention 13, 882-888 (2004).
|